Probes for the heterogeneity of muscimol binding sites in rat brain

Veronika I. Müller, Margot Ernst, Aygul Baykuchkarova, Filip Koniuszewski, Konstantina Bampali, Thomas Seidel, Petra ScholzeFrontiers in Pharmacology 2024 · DOI

Abstract

Muscimol, a psychoactive alkaloid from the Amanita muscaria mushroom, has long been regarded as a universal agonist for all GABA<sub>A</sub> receptor subtypes. However, recent pharmacological evidence suggests that its binding sites may be more heterogeneous than previously assumed. This study utilizes antipsychotic drugs—clozapine, loxapine, and chlorpromazine—as molecular probes to investigate the diversity of $^3$H-muscimol binding sites across different rat brain regions and recombinant receptor subtypes. Our results demonstrate that while the antagonist bicuculline displaces muscimol completely, antipsychotics exhibit partial and region-specific displacement. Computational modeling identifies the "Loop F" region of the $\alpha$ subunit as a key driver of this observed heterogeneity.

Introduction

GABA<sub>A</sub> receptors are pentameric ligand-gated ion channels that mediate fast inhibitory neurotransmission in the central nervous system. Composed of various subunits ($\alpha$1–6, $\beta$1–3, $\gamma$1–3, etc.), these receptors exhibit significant structural and functional diversity. Muscimol has traditionally been used as a gold-standard radioligand to label the orthosteric binding site across all subtypes. Recent observations, however, showed that antipsychotics like clozapine (CLZ) and loxapine (LOX) only partially displace $^3$H-muscimol in certain brain regions, suggesting the existence of multiple, pharmacologically distinct muscimol binding populations.

Methods

The study employed radioligand displacement assays using $^3$H-muscimol on membranes harvested from the rat hippocampus, cerebellum, thalamus, and striatum. Probes included bicuculline (BIC), LOX, CLZ, and chlorpromazine (CPZ). To isolate specific subtype responses, recombinant $\alpha$1$\beta$2, $\alpha$4$\beta$2, and $\alpha$6$\beta$2 receptors were expressed in HEK-293 cells. Structural insights were gained through in silico ligand analysis and molecular docking using AutoDock Vina, targeting high-resolution cryo-EM structures of GABA<sub>A</sub> receptors (PDB codes: 6HUK, 6X3S).

Results

Pharmacological assays revealed a consistent hierarchy of displacement potency across all brain regions: BIC > LOX > CLZ > CPZ. Crucially, while BIC achieved full displacement across all tested conditions, the antipsychotic probes showed varying degrees of partial displacement.

Figure 5: Bicuculline (BIC) demonstrates complete displacement of $^3$H-muscimol across tested conditions, reaching near-zero binding at high concentrations.

In contrast, clozapine (CLZ) displacement curves often plateaued, indicating that a significant fraction of muscimol binding sites remained insensitive to the drug. This partial displacement is a hallmark of the heterogeneity the researchers sought to map.

Figure 6: Clozapine (CLZ) exhibits partial displacement of $^3$H-muscimol, with curves leveling off above 50% binding, highlighting the presence of CLZ-insensitive sites.

Regional analysis showed that LOX-sensitive sites were less prevalent in the cerebellum (~50% displacement) compared to the hippocampus and striatum. In the striatum, combining LOX and CPZ increased total displacement, suggesting these drugs target overlapping but distinct receptor populations. Computational docking indicated that the diversity in binding is largely driven by the "Loop F" region of the $\alpha$ subunit, which acts as a structural filter for larger ligands like CLZ.

Discussion

These findings challenge the "universal" binding model of muscimol. The observed heterogeneity suggests that local subunit composition and stoichiometry significantly influence the pharmacology of the orthosteric site. The identification of Loop F as a primary determinant of ligand selectivity provides a structural basis for understanding why certain drugs fail to displace muscimol from all receptor populations. Future research utilizing concatenated receptors—where subunits are physically linked in a specific order—will be essential to definitively map specific subunit arrangements to these distinct pharmacological profiles.

Summary updated

Abstract

<b>Introduction:</b> The plant-based alkaloid muscimol is a potent agonist of inhibitory GABA<sub>A</sub>-neurotransmitter receptors. GABA<sub>A</sub> receptors are a heterogeneous family of pentameric complexes, with 5 out of 19 subunits assembling around the central anion pore. Muscimol is considered to bind to all receptor subtypes at the orthosteric drug binding site at the β+/α- interface. Recently, we observed that the antipsychotic drugs clozapine (CLZ), loxapine (LOX) and chlorpromazine (CPZ) although exerting functional inhibition on multiple GABA<sub>A</sub> receptor subtypes showed diverging results in displacing 3H-muscimol. While a complete displacement could be observed in hippocampal membranes by bicuculline (BIC), and no displacement with CPZ, the compounds CLZ and LOX competed partially. Non-sigmoidal, complex dose response curves were indicative of multiple sites. In the current study we now aimed to investigate more extensively this heterogeneity of bicuculline sensitive muscimol sites in rat brain. <b>Methods:</b> We tested membranes from four different brain regions (hippocampus, cerebellum, thalamus and striatum) and selected recombinantly expressed subunit combinations with displacement assays. 3H-muscimol displacement was tested with BIC, LOX, CLZ and CPZ. <i>In silico</i> ligand structural analysis and computational docking was performed. <b>Results:</b> We observed a unique pharmacology of each tested compound in the studied brain regions. Combining two of the tested ligands suggests that in striatum all CLZ sites are contained in the pool of LOX sites, while the CPZ sites may in part be non-overlapping with LOX sites. Experiments on recombinantly expressed receptors indicate, that BIC can displace 3H-muscimol from all tested receptors, while LOX and CLZ display different and variable competition indicative of multiple sites. Molecular docking produced structural correlates of the observed diversity of muscimol sites on the basis of bicuculline bound experimental structures. <b>Discussion:</b> These findings indicate that 3H-muscimol binding sites in rat brain are heterogeneous, with different populations of receptors, which are CPZ, LOX or CLZ sensitive or insensitive. These binding sites show a varying distribution in different rat brain regions. Molecular docking suggests that the so-called loop F region of α subunits drives the observed differences.
BibTeX
@inproceedings{muller2024probes,
  author = {Veronika I. Müller and Margot Ernst and Aygul Baykuchkarova and Filip Koniuszewski and Konstantina Bampali and Thomas Seidel and Petra Scholze},
  title = {{Probes for the heterogeneity of muscimol binding sites in rat brain}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2024.1368527},
}
Figure